Construction of a novel gene therapy lentiviral vector for drug resistant selection and detection in vivo.
- Author:
Chenyu XU
1
;
Ying GU
;
Wangheng HOU
;
Tong CHENG
;
Tao ZHANG
;
Yuqiong QUE
;
Shuangquan GAO
;
Jun ZHANG
;
Jiahuai HAN
;
Ningshao XIA
Author Information
1. National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Xiamen University, Xiamen 361005, China.
- Publication Type:Journal Article
- MeSH:
DNA Modification Methylases;
biosynthesis;
genetics;
DNA Repair Enzymes;
biosynthesis;
genetics;
Drug Resistance;
genetics;
Genetic Therapy;
methods;
Genetic Vectors;
genetics;
Humans;
Lentivirus;
genetics;
metabolism;
Luciferases;
biosynthesis;
genetics;
Tumor Suppressor Proteins;
biosynthesis;
genetics
- From:
Chinese Journal of Biotechnology
2008;24(2):256-261
- CountryChina
- Language:Chinese
-
Abstract:
Lentiviral vectors were powerful gene delivery tools for gene therapy. We developed a new lentiviral vector pBobi-MIL that constitutively expressed O6-methylguanine-DNAmethyltransferase (MGMT) and Luciferase, linked by the internal ribosomal entry site (IRES), to realize drug tolerance and real time monitoring in vivo. All results from RT-PCR, drug treating clones forming, immunofluorometric assay and chemiluminescence detection showed that cells infected by recombinant lentivirus L-MIL simultaneously expressed these two genes. This lays the foundation for the further research in gene therapy and can also help identify lentivirus titer.
